Regional Meetings 2018

Visiting Professors: Improving the Efficacy of Endocrine Treatment of Metastatic Breast Cancer — An Interactive Grand Rounds Series

Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of ER-positive metastatic breast cancer (mBC). Each session in this regional series will feature a blend of didactic presentation, interactive polling of attendees using keypad devices and follow-up audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services Department at or call (800) 233-6153.

Learn about our CNE series Endocrine Treatment of Metastatic Breast Cancer.

Schedule of Events:

Friday, September 28, 2018
7:00 AM – 8:00 AM
Education program

Matthew P Goetz, MD
Novant Health Presbyterian Medical Center
Charlotte, North Carolina

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised as seating is limited.

Each 1-hour session will include 4 topic modules focused on the current management of ER-positive mBC and strategies under active investigation. Each module will employ an identical format and may include:

  • Audience Polling
  • Display of Steering Committee Responses to Related Clinical Questions
  • Faculty Review of Select Data Sets
MODULE 1 Biologic and Pharmacologic Considerations MODULE 2 Available Clinical Research on Approved CDK4/6 Inhibitors; Use in Practice MODULE 3 Available Clinical Research on mTOR Inhibitors; Use in Practice MODULE 4 New Approaches to Endocrine Therapy

Each session will conclude with a 5-minute Q&A segment


Adam M Brufsky, MD, PhD
Professor of Medicine
Associate Director for Translational Investigation
University of Pittsburgh Cancer Institute
Co-Director, Comprehensive Breast Cancer Center
Associate Division Chief
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

Matthew P Goetz, MD
Professor of Oncology and Pharmacology
Mayo Clinic
Rochester, Minnesota

Sara A Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program, Division of Hematology/Oncology
University of California, Los Angeles
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Los Angeles, California
Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
Santa Monica, California

Ian E Krop, MD, PhD
Director of Clinical Research
Breast Oncology Center
Dana-Farber Cancer Institute
Chief, Breast Oncology Center
Susan F Smith Center for Women’s Cancers
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Joyce O’Shaughnessy, MD
Chair, Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Celebrating Women Chair in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Sara M Tolaney, MD, MPH
Dana-Farber Cancer Institute
Associate Director of Clinical Research
Susan F Smith Center for Women’s Cancers
Senior Physician
Assistant Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Denise A Yardley, MD
Senior Investigator, Breast Cancer Research
Sarah Cannon Research Institute
Tennessee Oncology PLLC
Nashville, Tennessee

Target Audience:
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of ER-positive mBC.

Learning Objectives:

  • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed mBC, considering clinical presentation (eg, age, menopausal status, comorbidities, symptomatology) and prior treatment course (eg, de novo metastatic disease, type and duration of adjuvant therapy).
  • Describe known and proposed mechanisms of resistance to hormonal therapy, and identify available therapies and investigational efforts attempting to leverage this knowledge.
  • Recognize the FDA approvals of palbociclib, ribociclib and abemaciclib for ER-positive mBC, and discern how these agents can be optimally employed in nonresearch patient care.
  • Educate patients regarding the unique side effects associated with approved CDK4/6 inhibitors, and develop preventive and emergent strategies to reduce or ameliorate these toxicities.
  • Identify clinical situations in which endocrine therapy alone or in combination with HER2-directed therapy should be considered in the management of ER-positive, HER2-positive mBC.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support:
These activities are supported by an educational grant from Lilly.